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Infections, tissue injury, and autoimmune disor-
ders all trigger a systemic inflammatory response. 
In patients, systemic inflammation often presents 
with sickness involving fever, anorexia, lethargy, 
and activation of the hypothalamus–pituitary–
adrenal axis (HPA axis). Symptoms of sickness 
are  thought  to  serve  an  adaptive  function  to 
combat infectious agents and they rely on specific 
pathways in the brain, mainly in the hypothala-
mus.  Previous  work  has  shown  that  various 
components  of  the  sickness  response  involve 
distinct neural structures (Dantzer et al., 2008). 
Upon immune challenge, leukocytes and endo-
thelial cells in the periphery release cytokines 
such  as  IL-1,  TNF,  and  IL-6,  which  sub-
sequently induce the sickness response. Thus, 
administration of IL-1 or other cytokines has 
served as an experimental model to investigate 
the mechanisms underlying the sickness response. 
Previous work has shown that fever and other 
components of the CNS response to systemic 
inflammation  require  both  cyclooxygenase  2 
(COX-2; PTGS2) and the induction of prosta-
glandin E2 (PGE2; Pecchi et al., 2009).
How peripheral inflammatory signals reach 
the brain to elicit central reactions is still a subject 
of debate. Four potential routes have been 
discussed (Dantzer et al., 2008). One theory sug-
gests that cytokines and endotoxins cross the 
blood–brain barrier within the circumventricu-
lar organs where the endothelium is fenestrated 
and act on microglia and other neural cells. A 
second hypothesis assumes that cytokines ac-
tivate  hypothalamic  nuclei  after  being  trans-
ported through brain endothelial cells. Third, 
peripheral inflammation could stimulate the 
vagus nerve that subsequently induces fever and 
sickness behavior. Finally, another hypothesis 
builds on the observation that cytokines or en-
dotoxins induce Cox-2 in brain vascular cells 
of the preoptic area close to thermoregulatory 
centers  and  in  other  hypothalamic  nuclei 
(Horai et al., 1998; Lacroix and Rivest, 1998; 
Gosselin and Rivest, 2008). By secreting PGE2 
into the parenchyma, endothelial cells are thought 
to stimulate neurons to induce fever and other 
aspects of the sickness response. However, direct 
evidence to support the function of brain endo-
thelial cells is still lacking. Moreover, other 
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Systemic inflammation affects the brain, resulting in fever, anorexia, lethargy, and activation 
of the hypothalamus–pituitary–adrenal axis. How peripheral inflammatory signals reach the 
brain is still a matter of debate. One possibility is that, in response to inflammatory stimuli, 
brain endothelial cells in proximity to the thermoregulatory centers produce cyclooxygenase 2 
(COX-2) and release prostaglandin E2, causing fever and sickness behavior. We show that 
expression of the MAP kinase kinase kinase TAK1 in brain endothelial cells is needed for 
interleukin 1 (IL-1)–induced COX-2 production. Exploiting the selective expression of 
the thyroxine transporter Slco1c1 in brain endothelial cells, we generated a mouse line 
allowing inducible deletion of Tak1 specifically in brain endothelium. Mice lacking the Tak1 
gene in brain endothelial cells showed a blunted fever response and reduced lethargy upon 
intravenous injection of the endogenous pyrogen IL-1. In conclusion, we demonstrate that 
TAK1 in brain endothelial cells induces COX-2, most likely by activating p38 MAPK and 
c-Jun, and is necessary for fever and sickness behavior.
© 2011 Ridder et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure 1.  In response to IL-1, TAK1 activates p38 MAPK and c-Jun and induces COX-2 and PGE2 in brain endothelial cells. (A) PBECs were 
pretreated for 30 min with 250 nM okadaic acid to prevent rapid TAK1 dephosphorylation and then stimulated with 50 ng/ml PBS or IL-1 for 10 min. 
Protein lysates were analyzed by Western blotting. A representative blot out of three independent experiments showing two samples per treatment group is 
displayed. (B–D) PBECs were stimulated with 50 ng/ml PBS or IL-1 for 30 min with or without 30-min pretreatment with 600 nM of the TAK1 inhibitor OZ. 
Protein lysates were analyzed by Western blotting to determine the phosphorylation of p38 MAPK, the band shift of c-Jun indicating its phosphorylation, 
and the degradation of IB. Densitometric quantifications are shown below the blots (n = 4–6). (E) bEnd.3 cells were stimulated with 50 ng/ml PBS, IL-1, 
or heat-inactivated IL-1 (IL-1 HI) for 2 h. COX-2 induction was analyzed by Western blotting. A representative example of two independent experiments 
is shown. IL-1 significantly (P < 0.05) induced COX-2 expression (densitometric COX-2/actin ratio 1.46 ± 0.14) compared with the PBS-group (1.00 ± 0.09) 
and the IL-1 HI–stimulated group (0.87 ± 0.11). IL-1 was heat inactivated at 90 °C for 60 min. (F) bEnd.3 cells were stimulated with 50 ng/ml PBS or IL-1 
for the indicated time period with or without 600 nM OZ. COX-2 induction was monitored by Western blotting. Densitometric quantifications are shown 
below the blot (n = 4). (G) PBECs were stimulated with 50 ng/ml IL-1 for 2 h with or without 30-min pretreatment with 600 nM OZ. Protein lysates were 
analyzed by Western blotting to detect COX-2. Densitometric quantifications are shown below the blot (n = 4). (H) PGE2 release by bEnd.3 cells was mea-
sured by ELISA 4 h after stimulation with 50 ng/ml IL-1, with or without 30-min pretreatment with 600 nM OZ (n = 5). PGE2 levels are expressed as units JEM Vol. 208, No. 13  2617
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relative to the untreated control. (I and J) Wild-type mice received i.p. injections of 30 mg/kg OZ or vehicle 30 min before administration of 30 µg/kg IL-1 
i.v. or PBS. 3 h later, the preoptic area was subject to immunostaining with antibodies against COX-2 and CD31. (I) Representative staining. (J) Quantifica-
tion of the COX-2 and CD31 double-positive area (normalized to the total area). n = 3–5 mice per group. (B–D, F–H, and J) Pooled data of at least two inde-
pendent experiments are shown. Values are means ± SEM. *, P < 0.05 (one-way ANOVA, Tukey’s post hoc test).
 
studies  have  localized  IL-1–induced  COX-2  expression 
mainly to perivascular macrophages and thus question the role 
of endothelial cells in this process (e.g., Serrats et al., 2010).
The best evidence that endothelial cells play a role in 
sickness comes from a recent study in which an impaired 
fever response to IL-1 was found in a mouse line expressing 
siRNA against the IL-1 receptor IL-1RI under control of 
the pan-endothelial Tie2 promoter/enhancer (Ching et al., 
2007). However, the diminished sickness response in this 
study may have been secondary to a mitigated systemic in-
flammatory reaction because the Tie2 promoter/enhancer is 
expressed in endothelial cells of all vascular beds. Indeed, 
endothelial cells play a key role in the systemic inflammatory 
reaction in vivo (Ye et al., 2008; Ding et al., 2009) and 
release the pyrogens PGE2 and IL-6 in response to IL-1 
(Warner et al., 1987; Jirik et al., 1989). In addition, IL-1 
induces its own expression in endothelial cells, providing a 
mechanism by which peripheral endothelial cells amplify the 
systemic inflammation (Warner et al., 1987).
To specifically test the role of brain endothelial cells in 
inducing fever and sickness behavior, we generated the 
Slco1c1-CreERT2 BAC transgenic mouse line that affords in-
ducible and cell-specific recombination in brain endothelial 
cells. Using this line, we delete the MAP kinase kinase kinase 
Tak1 (Map3k7) in brain endothelial cells because it is an im-
portant component of IL-1 signaling upstream of p38 MAPK 
and of the transcription factors NF-B and c-Jun that control 
Cox-2 gene transcription (Smith et al., 2000). Our data con-
firm that TAK1 is needed to activate p38 MAPK and c-Jun 
and to induce COX-2 in brain endothelial cells. Mice lacking 
Tak1 in brain endothelial cells (Slco1c1-CreERT2 × Tak1Fl/Fl 
mice) showed a blunted fever response and reduced lethargy 
upon i.v. stimulation with IL-1, whereas anorexia and corti-
costerone release were not affected by deleting Tak1. These 
data provide the first direct evidence that brain endothelial 
cells mediate the induction of fever and sickness behavior.
RESULTS AND DISCUSSION
TAK1 mediates p38 MAPK and c-Jun activation by IL-1  
in brain endothelial cells
To confirm that IL-1 activates TAK1, we stimulated pri-
mary brain endothelial cells (PBECs) with IL-1 and pre-
treated cells with the protein phosphatase inhibitor okadaic 
acid to prevent rapid dephosphorylation of TAK1. IL-1 
enhanced the phosphorylation of TAK1 as shown by the 
appearance  of  slower  migrating  forms  of  TAK1,  which 
have been shown to correspond to TAK1 phosphorylation 
(Hanada et al., 2001; Fig. 1 A).
We also investigated signaling pathways downstream of 
TAK1 that have been implicated in regulating Cox-2 levels 
(Smith et al., 2000). IL-1 stimulation increased phosphory-
lation of p38 MAPK in brain endothelial bEnd.3 cells, peaking 
at 10 min (not depicted), and in PBECs (Fig. 1 B). Preincu-
bating cells with the specific TAK1 inhibitor 5z-7-oxozeaenol 
(OZ; Ninomiya-Tsuji et al., 2003) reduced basal levels of 
p38 MAPK phosphorylation and blunted the IL-1–dependent 
increase in phosphorylation in bEnd.3 cells (not depicted) 
and in primary endothelial cells (Fig. 1 B). Furthermore, IL-1 
treatment induced phosphorylation of c-Jun, as indicated 
by the appearance of a c-Jun species with markedly reduced 
mobility in bEnd.3 cells (not depicted) and in primary endo-
thelial cells (Fig. 1 C). Inhibiting TAK1 by OZ diminished 
c-Jun phosphorylation.
IL-1 also activated NF-B as shown by the degradation 
of IB. Pretreatment of PBECs and bEnd.3 cells with OZ 
did not affect the activation of NF-kB (Fig. 1 D and not 
depicted). In addition, phosphorylation of IB as a further 
measure of NF-B activation upon stimulation with IL-1 
was not blocked by TAK1 inhibition either (unpublished 
data). These results are in accordance with previous studies 
showing that IL-1 is able to stimulate NF-B independently 
of TAK1 (Yamazaki et al., 2009). In brain endothelial cells, 
TAK1-independent pathways of NF-B activation seem to 
prevail. In summary, these data demonstrate that IL-1 
activates p38 MAPK and c-Jun in brain endothelial cells in a 
TAK1-dependent manner.
TAK1 mediates the induction of COX-2 and PGE2 by IL-1 
in brain endothelial cells
Stimulation of bEnd.3 cells with IL-1 transiently increased 
COX-2 protein levels after 2–8 h (Fig. 1, E and F). Heat-
inactivated IL-1 lost its ability to induce COX-2 expression in 
bEnd.3 cells, excluding a contamination with endotoxin (Fig. 1 E). 
The IL-1–induced increase of COX-2 in bEnd.3 cells was 
blocked by the TAK1 inhibitor OZ (Fig. 1 F). OZ also inhib-
ited COX-2 induction by IL-1 in PBECs (Fig. 1 G). Similarly, 
PGE2 levels in the supernatant rose 4 h after stimulating bEnd.3 
cells with IL-1, whereas TAK1 inhibition blocked this increase 
(Fig. 1 H). To investigate TAK1 inhibition in vivo, we i.p. in-
jected mice with OZ 30 min before i.v. administration of IL-1. 
Inhibition of TAK1 with OZ blocked the IL-1–stimulated in-
crease in COX-2 expression in CD31-positive brain endothelial 
cells in the preoptic area (Fig. 1, I and J). These results indicate 
that in brain endothelial cells, TAK1 induces COX-2 and 
subsequently stimulates the secretion of PGE2, an important 
mediator of the sickness response. In accordance with our data 
that TAK1 has no significant effect on NF-B signaling, Cox-2 
induction by IL-1 in endothelial cells is known to be con-
trolled by the MAP kinases p38 and JNK and only partially 
depends on NF-B activity (Kuldo et al., 2005).2618 Fever and lethargy require TAK1 in brain endothelium | Ridder et al.
The solute carrier organic anion transporter 1c1 (Slco1c1, 
Oatp14) has previously been reported to be selectively ex-
pressed in endothelial cells of the brain and in choroid plexus 
epithelial cells (Roberts et al., 2008). By immunofluorescent 
double staining of SLCO1C1 and CD31 as an endothelial 
marker, we verified that endothelial cells express SLCO1C1 
in the brain of adult mice (unpublished data). Real-time RT-
PCR confirmed the selective expression of Slco1c1 in the brain 
and spinal cord of adult mice (Lang et al., 2011). Therefore, 
we inserted the inducible CreERT2 in the Slco1c1 locus to 
generate a BAC-transgenic mouse line. CreERT2 was chosen to 
exclude effects of gene deletion during embryonic and postnatal 
Slco1c1-CreERT2 mice allow brain  
endothelial-specific recombination
To investigate the role of Tak1 specifically in brain endothe-
lial cells in the sickness response in vivo, we used a conditional 
approach. To our knowledge, mouse lines expressing Cre 
recombinase under the control of endothelial cell–specific 
promoters have not been used to address the role of brain 
endothelial cells in the sickness response, possibly because of 
poor recombination rates in the CNS. For example, mice 
expressing Cre recombinase under the control of the tie2 
locus (Korhonen et al., 2009) show nearly no recombina-
tion in the brain (S. Offermanns, personal communication). 
Figure 2.  Brain endothelial-specific recombination in Slco1c1-CreERT2 mice. (A) The preoptic area of Slco1c1-CreERT2; Ai14 mice treated with 
tamoxifen was subjected to immunostaining with anti-CD31. tdTomato reporter is shown in the middle. Representative stainings from three independent 
experiments are shown. (B) Histochemical -Galactosidase staining of several organs of Slco1c1-CreERT2; Rosa26 mice treated with tamoxifen. Represen-
tative stainings from three independent experiments are shown. (C) Heart cryosections of tamoxifen-treated Slco1c1-CreERT2; Ai14 reporter mice stained 
with anti-CD31. 3.2 ± 1.6% of all CD31-positive endothelial cells in the heart were expressing the reporter tdTomato (arrow). Representative stainings 
from two independent experiments are shown. (D) Immunostaining of brain cryosections of tamoxifen-treated Slco1c1-CreERT2; Rosa26 mice with anti–
-Galactosidase and anti-CD31 to analyze recombination in epithelial and in endothelial cells of the choroid plexus. Representative stainings from two 
independent experiments are shown. (E–G) Immunofluorescent staining for CD11b, NeuN, and GFAP to determine potential recombination in macro-
phages/microglia, neurons, and astrocytes in the preoptic area of Slco1c1-CreERT2; Ai14 reporter mice, treated with tamoxifen. Representative stainings 
from three independent experiments are shown. (H) The cortex of Slco1c1-CreERT2; Ai14 reporter mice treated with tamoxifen was subjected to immuno-
staining with anti-GFAP. tdTomato showed recombination in endothelial cells surrounded by GFAP-positive astrocytic end-feet. In addition, in the cortex 
a small number of astrocytes had undergone recombination (arrow). Representative stainings from three independent experiments are shown.JEM Vol. 208, No. 13  2619
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observed recombination in epithelial cells, but not in endo-
thelial cells of the choroid plexus (Fig. 2 D).
In Slco1c1-CreERT2; Ai14 mice, immunohistochemistry 
demonstrated that tdTomato-expressing cells were negative 
for CD11b, a marker for microglia and macrophages, for the 
neuronal marker NeuN, and for the astrocytic marker GFAP 
(Fig. 2, E–G), with the exception of granule cells in the den-
tate gyrus of the hippocampus (not depicted). Some tdTomato-
expressing cells in the cortex did not show a vascular shape 
and were CD31 negative. We identified these cells as GFAP-
positive astrocytes (Fig. 2 H). In primary cortical cultures 
from  adult  Slco1c1-CreERT2;  Ai14  mice,  7%  of  S100-
positive  astrocytes  were  tdTomato  positive,  indicating   
recombination. -SMA–positive pericytes and IBA1-positive 
development (Lang et al., 2011). Slco1c1-CreERT2 mice were 
crossed with the reporter mouse line Ai14 to investigate re-
combination (Madisen et al., 2010). After injecting tamoxi-
fen, the reporter tdTomato was colocalized with CD31 in all 
blood vessels of the brain, showing widespread recombina-
tion in brain endothelial cells (Fig. 2 A). This finding was 
confirmed when Slco1c1-CreERT2 animals were crossed with the 
Rosa26 -Galactosidase reporter line (Soriano, 1999; Fig. 2 B). 
In contrast, no signs of recombination were found in pe-
ripheral organs such as liver, kidney, lung, and intestine. In 
aorta, heart, and testis, only a small number of cells were pos-
itive for the reporter -Galactosidase or tdTomato (Fig. 2, 
B and C). In accordance with SLCO1C1 expression in 
choroid plexus epithelial cells (Roberts et al., 2008), we also 
Figure 3.  Slco1c1-CreERT2 x Tak1Fl/Fl mice show a blunted fever response and reduced sickness behavior upon stimulation with IL-1. (A) Lysates of 
PBECs from indicated mice were analyzed by Western blotting. One out of three independent experiments is demonstrated. (B) The rise in body temperature in 
Slco1c1-CreERT2 × Tak1Fl/Fl mice in comparison to control Tak1Fl/Fl mice (n = 7–8 per genotype) upon administration of 30 µg/kg IL-1 i.v. Values are means ± SEM. 
*, P < 0.05 (repeated measures two-way ANOVA and Bonferroni’s post-test). Pooled data of two independent experiments are shown. (C) IL-1 (30 µg/kg) influ-
ence on locomotor activity of Slco1c1-CreERT2 × Tak1Fl/Fl mice and control Tak1Fl/Fl mice (n = 7–8 per group). The ratio of the activity of IL-1– and PBS-injected 
animals in the dark phase is shown. Values are means ± SEM. *, P < 0.05 (Student’s t test). (D) IL-1 administration influence on food intake over 22 h in Slco1c1-
CreERT2 × Tak1Fl/Fl mice and Tak1Fl/Fl mice. Values are means ± SEM. *, P < 0.05 (one-way ANOVA, Tukey’s post hoc test). (E) Weight loss of Slco1c1-CreERT2 × Tak1Fl/Fl  
mice and control Tak1Fl/Fl mice over 22 h after i.v. administration of IL-1. Values are means ± SEM. (F) Plasma corticosterone levels 3 h after IL-1 and PBS 
administration in Slco1c1-CreERT2 × Tak1Fl/Fl mice and control Tak1Fl/Fl mice. Values are means ± SEM (n = 6–7 animals per group). *, P < 0.05 (one-way ANOVA, 
Tukey’s post hoc test). Pooled data of two independent experiments are shown. (G) Lysates from the hypothalamus of mice deficient for Tak1 in neurons, oligo-
dendrocytes, and astrocytes (Nestin-Cre × Tak1Fl/Fl mice) and Tak1Fl/Fl mice were analyzed by Western blotting. One out of two independent experiments is shown. 
(H) The rise in body temperature in Nestin-Cre × Tak1Fl/Fl mice in comparison with Tak1Fl/Fl mice (n = 8 per genotype) upon administration of 30 µg/kg IL-1 i.v. 
Values are means ± SEM. Pooled data of two independent experiments are shown. (I) IL-1 (30 µg/kg) influence on locomotor activity of Nestin-Cre × Tak1Fl/Fl 
mice and control Tak1Fl/Fl mice (n = 8 per group). The ratio of the activity of IL-1 and PBS injected animals in the dark phase is shown. Values are means ± SEM.2620 Fever and lethargy require TAK1 in brain endothelium | Ridder et al.
In summary, these data demonstrate that TAK1 in brain 
endothelial cells is an important mediator of immune-to-brain 
communication and is necessary for full development of the 
sickness response. In response to the endogenous pyrogen 
IL-1, TAK1 activated p38 MAPK and c-Jun and increased 
COX-2 expression and PGE2 production in brain endothe-
lial cells. Fever and lethargy, two main features of the sickness 
response, were reduced in Slco1c1-CreERT2 × Tak1Fl/Fl mice, 
demonstrating the importance of brain endothelial cells in the 
mutual communication between CNS and the immune sys-
tem. A key role of brain endothelial cells in the sickness re-
sponse is compatible with previous work using bone marrow 
transplantation to generate chimeric mice, in which the geno-
type of hematopoietic cells, including brain perivascular 
macrophages, differs from that of all other cells of the body 
(Chakravarty and Herkenham, 2005; Steiner et al., 2006a; 
Wisse et al., 2007; Gosselin and Rivest, 2008). These studies 
provided evidence that nonhematopoietic cells are involved 
in the sickness response but could not further define the cell 
types involved. Interestingly, we also found Tak1 mRNA in 
the choroid plexus. Tak1 mRNA levels in the plexus were 
reduced in Slco1c1-CreERT2 × Tak1Fl/Fl mice (0.5 ± 0.1 rela-
tive units) compared with Tak1Fl/Fl mice (1.1 ± 0.2 relative 
units; P < 0.05, Student’s t test). The choroid plexus has been 
shown to express COX-2 and other inflammatory mediators 
after stimulation of the peripheral immune system (Lacroix 
and Rivest, 1998; Gosselin and Rivest, 2008). Because COX-2 
expression  is  mainly  localized  to  vascular  structures  and 
macrophages  in  the  choroid  plexus  (Lacroix  and  Rivest, 
1998; Dantzer et al., 2008), it seems unlikely that recombina-
tion of the Tak1 gene in epithelial cells of the plexus (Fig. 2 D) 
could additionally contribute to the blunted sickness response 
in Slco1c1-CreERT2 × Tak1Fl/Fl mice.
The fact that IL-1–induced anorexia, weight loss, and 
induction of plasma corticosterone did not differ between 
genotypes in our experiments illustrates that there are several 
ways of immune-to-brain interaction (Dantzer et al., 2008). 
Within brain endothelial cells, not all inflammatory pathways 
depend on TAK1. The TAK1-independent activation of 
NF-B (Fig. 1 D) may induce IL-6, TNF, or other mediators 
that contribute to the sickness response. Thus, our data based 
on the selective deletion of Tak1 may underestimate the role 
of brain endothelial cells in the sickness response.
Another hypothesis would be that some facets of the   
sickness response, such as anorexia, weight loss, and HPA   
axis activation, use other cellular routes of immune-to-brain 
signaling  independent  of  the  endothelium.  Inflammatory 
mediators induce anorexia by activating POMC-expressing 
neurons in the arcuate nucleus (Jang et al., 2010). This site of 
action is in close proximity to the median eminence, a cir-
cumventricular organ lacking the blood–brain barrier. Thus, 
IL-1 may directly act on POMC neurons to inhibit feeding. 
Alternatively, the vagal nerve has been proposed to mediate 
anorexia in response to IL-1 (Bret-Dibat et al., 1995), pro-
viding a possible mechanism underlying anorexia indepen-
dent of endothelial function. Interestingly, a recent study has 
microglia/macrophages in culture never expressed tdTomato. 
In summary, the Slco1c1-CreERT2 mouse line allows induc-
ible recombination in endothelial cells of the brain but not in 
other vascular territories.
Brain endothelial-specific deletion of Tak1 interferes  
with the sickness response
We deleted Tak1 in brain endothelial cells (Slco1c1-CreERT2 × 
Tak1Fl/Fl) by crossing mice carrying Tak1 alleles flanked by 
loxP sites (Tak1Fl/Fl) with Slco1c1-CreERT2 mice (Sato et al., 
2005). TAK1 expression in PBECs of Slco1c1-CreERT2 × 
Tak1Fl/Fl mice was markedly reduced at the protein (Fig. 3 A) 
and the mRNA level (Tak1Fl/Fl, 1.1 ± 0.3 relative units; 
Slco1c1-CreERT2 × Tak1Fl/Fl, 0.3 ± 0.1 relative units, P < 0.05, 
Student’s t test). Slco1c1-CreERT2 × Tak1Fl/Fl mice had a nor-
mal body temperature (unpublished data). However, IL-1 
induced only a short-lasting fever response in Slco1c1-CreERT2 ×   
Tak1Fl/Fl mice in comparison with Tak1Fl/Fl controls (Fig. 3 B). 
The fact that the early fever response to IL-1 remained 
intact in Slco1c1-CreERT2 × Tak1Fl/Fl mice is consistent with 
the finding that peripheral PGE2 release mediates the early 
temperature rise upon immune challenge (Steiner et al., 
2006b). Injecting IL-1 at 10 a.m. reduced spontaneous loco-
motion the next night. Locomotion was reduced less in   
Slco1c1-CreERT2 × Tak1Fl/Fl mice than in Tak1Fl/Fl controls 
(Fig. 3 C), indicating that TAK1 in brain endothelial cells 
mediates fever and lethargy in response to IL-1. In contrast, 
we found no change in IL-1–induced anorexia (Fig. 3 D). 
Body weight also dropped to a similar extent in Tak1Fl/Fl and 
Slco1c1-CreERT2 × Tak1Fl/Fl mice (Fig. 3 E). In addition, cor-
ticosterone plasma levels, as a measure for HPA axis activa-
tion, rose to a similar extent in Tak1Fl/Fl and Slco1c1-CreERT2 × 
Tak1Fl/Fl mice (Fig. 3 F) at the time point 3 h after IL-1 
stimulation that we have investigated.
Recently, astrocytes have been implicated in the induc-
tion of fever and sickness behavior (Hanada et al., 2009). We 
found recombination in a few cortical astrocytes of Slco1c1-
CreERT2 mice (Fig. 2 H) and, therefore, we wanted to test 
the role of astrocytic TAK1 in the sickness response. Tak1 
was deleted in astrocytes, oligodendrocytes, and neurons by 
crossing Tak1Fl/Fl mice with transgenic mice expressing the Cre 
recombinase under control of the Nestin promoter (Nestin-Cre × 
Tak1Fl/Fl; Tronche et al., 1999). Western blotting confirmed 
that TAK1 levels were markedly reduced in hypothalamic 
extracts of Nestin-Cre × Tak1Fl/Fl mice (Fig. 3 G). Nestin-Cre × 
Tak1Fl/Fl mice did not show an obvious phenotype. The IL-1–
induced  fever  response  and  the  inhibition  of  locomotion 
were not impaired in Nestin-Cre × Tak1Fl/Fl mice (Fig. 3, 
H and I). This shows that TAK1 in astrocytes, oligodendro-
cytes, or neurons is not involved in fever or lethargy evoked 
by administering IL-1. Additionally, IL-1 induced a simi-
lar fever response and reduction in locomotion in Slco1c1-
CreERT2 mice without a floxed allele when compared with 
wild-type  littermates  (unpublished  data).  This  excludes  a 
confounding effect of the brain endothelial CreERT2 expres-
sion itself on the IL-1–induced sickness response.JEM Vol. 208, No. 13  2621
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homogenized in a Dounce homogenizer, and the resulting homogenate was 
centrifuged at 2,000 g for 7 min. The pellet was resuspended in 18% dextran 
solution (mol wt 60,000–90,000; Sigma-Aldrich) in DME-F12 (Invitrogen) 
and centrifuged at 7,840 g for 10 min. After removing the supernatant and 
myelin debris, the pellet was resuspended in DME (Invitrogen) containing   
1 mg/ml collagenase/dispase (Roche), 40 µg/ml DNase 1 (Roche), and 
0.147 µg/ml tosyllysine chloromethyl ketone (Sigma-Aldrich) and incubated 
at 37°C for 75 min with occasional agitation to free endothelial cells from   
pericytes, perivascular macrophages, and remains of the basement membrane. 
The cell suspension was centrifuged at 2,000 g for 7 min, the supernatant was 
discarded, and cells were washed and seeded in 6-well plates coated with 
mouse collagen IV (BD). Cells were grown in DME-F12 supplemented 
with 20% plasma-derived horse serum (First Link), 2 mM l-glutamine, 
100 IU/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B, 
100 U/ml heparin (Braun), and 30 µg/ml of endothelial cell growth supple-
ment (Sigma-Aldrich). 4 µg/ml puromycin (Sigma-Aldrich) was added for 
the first 48 h after preparation to deplete cells of nonendothelial origin. To 
prepare primary mixed cortical cultures, cortices of adult mice were dissected, 
homogenized, and digested with trypsin and DNase 1. Cells were grown in 
DME-F12 supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml 
streptomycin, and 0.5 mM l-glutamine. The mouse brain endothelial cell 
line bEnd.3 (American Type Culture Collection) was grown in DME con-
taining 4.5 g/liter glucose, FCS (10%), 100 IU/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM l-glutamine.
Western blots. PBECs and bEnd.3 cells were cultured on 6-well plates. A 
preincubation with 250 nM okadaic acid or with 600 nM OZ for 30 min 
was performed as indicated. Cells were stimulated with 50 ng/ml of mouse 
IL-1 for the indicated times and lysed in 2× hot Laemmli buffer, incubated 
at 95°C for 5 min, and then loaded on SDS-PAGE gels.
Mice were deeply anesthetized with 200 µl 2.5% tribromoethanol per 10 g 
of body weight and perfused with ice-cold Ringer’s solution. Hypothalamic 
tissue samples were homogenized in radioimmunoprecipitation (RIPA) 
buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% SDS, 
1% Triton X-100, 0.5% sodium deoxycholate, and 0.5 mM PMSF) supple-
mented with phosphatase inhibitor cocktails 1+2 (Sigma-Aldrich) and prote-
ase inhibitor tablets (Roche). Lysates were subjected to SDS-PAGE.
The membranes were then incubated with the indicated primary antibodies 
and, consequently, with HRP-conjugated secondary antibodies. For detection 
we applied enhanced chemiluminescence (ECL; Thermo Fisher Scientific).
PGE2-ELISA. bEnd.3 cells were cultured on 6-well plates, preincubated with 
600 nM OZ or DMSO for 30 min, and then treated with 50 ng/ml mouse 
IL-1 or PBS for 4 h. The supernatant was collected and the PGE2-ELISA 
(Cayman Chemical) was performed according to the manufacturer’s description.
Immunofluorescence. Mice were deeply anesthetized by i.p. injection of 
2.5%  tribromoethanol  (200  µl/10  g  of  body  weight)  and  perfused  with 
Ringer’s solution, followed by 4% PFA in PBS. Brains were postfixed for 
4 h in 4% PFA in PBS and immersed in 30% sucrose in PBS overnight. Coro-
nal cryosections were stained free floating overnight with the indicated pri-
mary antibodies. Alexa Fluor 488–labeled (Invitrogen) and Cy3-labeled 
(Jackson ImmunoResearch Laboratories) secondary antibodies were used for 
detection. For COX-2/CD31 immunofluorescence, we perfused mice only 
with Ringer’s solution, froze brains on dry ice, and stained 20-µm cryosec-
tions on slides. We quantified the COX-2/CD31 double-positive area with 
ImageJ software (National Institutes of Health). 
Quantitative  RT-PCR.  RNA  from  PBECs  and  choroid  plexus  from 
tamoxifen-treated mice were isolated using the RNeasy Mini kit (QIAGEN), 
according to the manufacturer’s protocol, and transcribed with Moloney 
Murine  Leukemia  Virus  reverse  transcription  and  random  hexamer 
primers (Promega). The following primers were used: Cyclophilin A for-
ward, 5-AGGTCCTGGCATCTTGTCCAT-3; Cyclophilin A reverse,   
5-GAACCGTTTGTGTTTGGTCCA-3, PCR product 51 bp; Tak1 
forward, 5-AGAGGTTGTCGGAAGAGGAGCTT-3; and Tak1 reverse, 
implicated perivascular macrophages in the neuroendocrine 
response to IL-1 (Serrats et al., 2010). By ablating brain 
perivascular macrophages with clodronate liposomes, Serrats 
et al. (2010) found that brain perivascular macrophages mediate 
the  activation of  the  HPA axis  and  its neuronal  circuitry 
evoked  by  administering  IL-1.  However,  macrophage 
depletion had no effect on IL-1–induced lethargy and fever 
response to IL-1 administration (Serrats et al., 2010). Inter-
estingly, according to our study, lethargy and fever, but not 
HPA axis activation, depend on endothelial cells, supporting 
the hypothesis that individual components of the sickness 
response depend differently on distinct cell types.
MATERIALS AND METHODS
Chemicals and antibodies. For Western blotting and immunofluores-
cence, the following antibodies and dilutions were used: anti-TAK1 1:500 
(Millipore), anti-p38 1:1,000, anti–phospho-p38 1:1,000, anti–c-Jun 1:1,000, 
anti–phospho-c-Jun 1:1,000, anti–phospho-TAK1 1:1,000, anti–phospho-
IB  1:1,000  (Cell  Signaling  Technology),  anti-IB  1:500,  anti-actin 
1:1,000  (Santa  Cruz  Biotechnology,  Inc.),  anti–COX-2  1:500/1:900 
(Western blot/immunofluorescence; Cayman Chemical), anti-NeuN 1:100   
(Millipore), anti-GFAP 1:500 (Dako), anti-CD31 1:300 (BD), anti-CD11b 
1:100 (Serotec), anti-SLCO1C1 1:500 (provided by L. Roberts, Xenoport, 
Santa Clara, CA), and anti–-Galactosidase 1:2,000 (Millipore). Tribromo-
ethanol and tamoxifen were obtained from Sigma-Aldrich. OZ was purchased 
from AnalytiCon Discovery. Okadaic acid was obtained from EMD. Re-
combinant  mouse  IL-1  (endotoxin  content  <0.1  ng/µg  IL-1)  was 
purchased from PeproTech.
Mice. A bacterial artificial chromosome (BAC; RP24-85B20) was chosen 
that harbors the mouse Slco1c1 locus with an 80-kb 5-upstream and an   
81-kb 3-downstream region. To modify the BAC, a similar strategy was used 
as described previously (Lang et al., 2011). In brief, the BAC was modified by 
homologous recombination to insert a cassette encoding a codon-improved 
Cre recombinase (iCre), a mutated ligand-binding domain of the human 
estrogen receptor (ERT2), and an ampicillin resistance cassette flanked by two 
FRT sites. The construct was linearized and electroporated into heat-induced 
EL250 bacteria harboring the BAC. Clones with the recombinant BAC were   
induced with l-arabinose to express FLP recombinase, which resulted in 
deletion of the ampicillin resistance cassette. The modified genomic fragment 
containing the iCreERT2 knockin at the ATG of the Slco1c1 gene was 
separated from the BAC backbone by NotI digestion and subsequent purifi-
cation with Sepharose CL4b Column (GE Healthcare). The DNA was micro-
injected into the B6D2F1 hybrid mouse pronuclei. Transgenic offspring was 
identified by genotyping PCR from tail DNA. The following primers were 
used for genotyping: Rec1_UB5, 5-CTCGAGGAAGTTCCTATTCTC-3; 
and Rec1_DB3, 5-TCTCTGTCTCCTCTGCTTATC-3.
To verify activity and localization of the CreERT2 fusion protein,   
Slco1c1-CreERT2  mice  were  mated  with  animals  of  the  Cre  reporter  lines 
Gt(ROSA)26Sortm1sor  (ROSA26)  (Soriano,  1999)  and  B6.Cg-Gt(ROSA) 
26Sortm14(CAG-tdTomato)Hze/J (Ai14) (Madisen et al., 2010). For histologi-
cal analysis of -Galactosidase activity, histochemical stainings were performed 
on 40-µm cryosections, followed by eosin counterstaining as described 
previously (Korhonen et al., 2009). Tak1Fl/Fl mice (Sato et al., 2005) were pro-
vided by S. Akira (Laboratory of Host Defense, Osaka University, Osaka,   
Japan). All Slco1c1-CreERT2 animals used in this study were treated with   
1 mg tamoxifen every 12 h for 5 d. All animal experiments were approved by 
the local animal ethics committee (Regierungspräsidium Karlsruhe; Ministe-
rium für Landwirtschaft, Umwelt und ländliche Räume, Kiel, Germany).
Cell isolation and culture. PBECs were prepared from 2–6-mo-old ani-
mals that had been injected with tamoxifen at the age of 5–6 wk in the case 
of genetically modified mice. Animals were sacrificed with CO2, and the 
cerebrum was isolated and dissected free of the meninges. The brain was 2622 Fever and lethargy require TAK1 in brain endothelium | Ridder et al.
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5-ACAACTGCCGGAGCTCCACAA-3, PCR product 128 bp. Quanti-
tative RT-PCR was performed according to the following protocol: 2 min 
at 50°C, 2 min at 95°C, 15 s at 95°C, and 1 min at 60°C (40 cycles). Ampli-
fication was quantified using Platinum SYBR Green qPCR SuperMix 
(Invitrogen).  Quantified  results  for  Tak1  cDNA  was  normalized  to   
Cyclophilin A using the Ct method.
Mouse treatment and telemetric temperature and activity measure-
ments. OZ (30 mg/kg body weight) or vehicle (DMSO) was administered 
i.p. 30 min before IL-1 injection. Recombinant IL-1 was reconstituted in 
water to a concentration of 0.1 µg/µl and further diluted with PBS. Mice 
were injected retroorbitally under brief ether anesthesia (<60 s) with PBS or 
mouse IL-1 (30 µg/kg body weight). We used a radiotelemetry system 
(Data Sciences International) to monitor temperature and activity in con-
scious, unrestrained mice. Mice were kept at a room temperature of 25 ± 
1°C and had ad libitum access to food and water. After i.p. implantation of 
the transmitters (TA-F20; DSI), mice were allowed to recover for at least 
7 d. Mice were injected i.v. between 9:30 and 10:30am with PBS and, 2 d 
later, with mouse IL-1. We collected data over a period of 10 s every min-
ute and averaged over 30 min to measure temperature or over the whole 
dark phase to measure activity. Weight loss and food intake were determined 
22 h after the injection.
Corticosterone measurement. 3 h after i.v. injection of IL-1 (30 µg/kg 
body weight), mice were anesthetized by i.p. injection of 150 µl 2.5% tribro-
moethanol/10 g of body weight, and blood samples were drawn from the 
vena cava. Plasma corticosterone levels were measured by RIA in the Ste-
roid Laboratory of the Institute of Pharmacology, Heidelberg, Germany.
Statistical analysis. Values are expressed as means ± SEM. Differences 
between two groups were analyzed by using the unpaired two-sided Stu-
dent’s t test. The effect of IL-1 on body temperature was determined by 
subtracting the temperatures that were measured after PBS injection. To 
analyze temperature differences, repeated measures two-way ANOVA and 
Bonferroni’s post-test were used. For all other data, one-way ANOVA, 
followed by Tukey’s multiple comparison test, was used. Data were consid-
ered to be significant at P < 0.05.
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